Abstract IA015: Is salpingectomy as effective as bilateral salpingo-oophorectomy in preventing ovarian, fallopian tube, and peritoneal cancer? Let’s prove it!

Abstract Since ovarian cancer screening does not reduce ovarian cancer mortality, the main focus to reduce ovarian cancer mortality is prevention. For individuals at increased risk of ovarian carcinoma, risk-reducing bilateral salpingo-oophorectomy (RRSO) is highly effective, but uptake at the recommended age is suboptimal, likely due to concerns about premature menopause. Mounting evidence suggests that many “ovarian” cancers originate in the fallopian tube, making bilateral salpingectomy with delayed oophorectomy an attractive, but as of yet, unproven option for risk-reduction in those who decline RRSO. This talk will review the scientific evidence supporting a tubal origin of ovarian cancer, preliminary data supporting the safety and possible efficacy of salpingectomy and will discuss two prospective clinical trials powered to test the hypothesis that bilateral salpingectomy with delayed oophorectomy is non-inferior to RRSO to reduce the incidence of ovarian, fallopian tube, and peritoneal cancer among mutation carriers at high risk of ovarian cancer. Citation Format: Kathryn P. Pennington. Is salpingectomy as effective as bilateral salpingo-oophorectomy in preventing ovarian, fallopian tube, and peritoneal cancer? Let’s prove it! abstract. In: Proceedings of the AACR Special Conference on Ovarian Cancer; 2023 Oct 5-7; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84 (5 Suppl₂): Abstract nr IA015.